

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

JANUARY 5, 2004

Date of Report (Date of earliest event reported)

ORAGENICS, INC.

(Exact name of registrant as specified in its charter)

FLORIDA	333-100568	59-3410522
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

12085 RESEARCH DRIVE
ALACHUA, FLORIDA 32615

(Address of principal executive offices including zip code)

(386) 418-4018

Registrant's telephone number, including area code

NONE

(Former name or former address, if changed since last report.)

ITEM 7. FINANCIAL INFORMATION AND EXHIBITS

EXHIBIT NO. DESCRIPTION

99.1 Press Release

ITEM 9. REGULATION FD DISCLOSURE

Oragenics, Inc. announces today that all Series A common stock warrants have been exercised and that it has engaged MontRidge, LLC to provide investor relations consulting services.

SIGNATURES

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on this 5th day of January, 2004.

ORAGENICS, INC.
(REGISTRANT)

BY: /s/ Mento A. Sponis

Mento A. Sponis
President, Principal Executive
Officer and a member of the Board of
Directors.

Contact:
Mento A. "Chuck" Sponis
Chief Executive Officer
Oragenics, Inc.
(386) 418-4018

FOR IMMEDIATE RELEASE

ORAGENICS RECEIVES \$2.4 MILLION THROUGH WARRANT EXERCISE

COMPANY RETAINS INVESTOR RELATIONS FIRM.

ALACHUA FL (JANUARY 5, 2004) - Oragenics, Inc. (TSX-V: ORA.U) announced today that all warrant holders exercised their Series A warrants which were to expire December 24, 2003. Exercise of the 1,200,000 Series A warrants at the \$2.00 exercise price resulted in a total of \$2.4 million (U.S.) received by the Company.

The Company also announced that it had retained MontRidge LLC to serve as its investor relations consultant beginning in January of 2004. Since 1991 MontRidge has worked closely with biotechnology industry clients to achieve their financing goals. MontRidge is located in Ridgefield, Connecticut.

Oragenics, Inc. is an emerging biotechnology research and development company that began operations in 1999. Located in Alachua, Florida at the University of Florida's Sid Martin Biotechnology Development Incubator, Oragenics is developing three new healthcare products. The most advanced product is an oral rinse for the prevention of tooth decay, which is anticipated to enter clinical trials in 2004. The second product in pre-clinical development is a broad-spectrum antibiotic. Oragenics is also developing a probiotic product to maintain oral health. For more information about Oragenics, please consult the Company's website at www.oragenics.com.

#####

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this news release.